bluebird bio Inc (BLUE) Insider David Davidson Sells 4,000 Shares

bluebird bio Inc (NASDAQ:BLUE) insider David Davidson sold 4,000 shares of bluebird bio stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $202.36, for a total transaction of $809,440.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

David Davidson also recently made the following trade(s):

  • On Monday, January 8th, David Davidson sold 3,522 shares of bluebird bio stock. The stock was sold at an average price of $173.61, for a total transaction of $611,454.42.
  • On Wednesday, January 3rd, David Davidson sold 6,000 shares of bluebird bio stock. The stock was sold at an average price of $180.30, for a total transaction of $1,081,800.00.

Shares of bluebird bio Inc (NASDAQ BLUE) opened at $202.90 on Thursday. The stock has a market cap of $9,702.70, a price-to-earnings ratio of -28.90 and a beta of 2.07. bluebird bio Inc has a fifty-two week low of $71.25 and a fifty-two week high of $222.03.

BLUE has been the topic of several recent analyst reports. Wedbush restated an “outperform” rating and set a $174.00 price objective (up from $135.00) on shares of bluebird bio in a research report on Thursday, November 2nd. Maxim Group raised their price objective on shares of bluebird bio from $170.00 to $200.00 and gave the company a “buy” rating in a research report on Thursday, November 30th. Cantor Fitzgerald restated a “sell” rating and set a $58.00 price objective (up from $39.00) on shares of bluebird bio in a research report on Wednesday, November 1st. Barclays restated an “overweight” rating and set a $209.00 price objective (up from $162.00) on shares of bluebird bio in a research report on Wednesday, December 13th. Finally, Morgan Stanley upgraded shares of bluebird bio from an “underweight” rating to an “equal weight” rating in a research report on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. bluebird bio currently has an average rating of “Hold” and a consensus price target of $161.45.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Cornerstone Capital Management Holdings LLC. increased its holdings in bluebird bio by 0.8% in the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 17,955 shares of the biotechnology company’s stock valued at $1,885,000 after acquiring an additional 140 shares during the last quarter. Prudential Financial Inc. increased its holdings in bluebird bio by 4.0% in the 2nd quarter. Prudential Financial Inc. now owns 3,882 shares of the biotechnology company’s stock valued at $408,000 after acquiring an additional 150 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in bluebird bio by 0.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,433 shares of the biotechnology company’s stock valued at $3,302,000 after acquiring an additional 151 shares during the last quarter. Ameritas Investment Partners Inc. increased its holdings in bluebird bio by 5.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,600 shares of the biotechnology company’s stock valued at $378,000 after acquiring an additional 191 shares during the last quarter. Finally, BNP Paribas Arbitrage SA increased its holdings in bluebird bio by 6.5% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 5,444 shares of the biotechnology company’s stock valued at $748,000 after acquiring an additional 330 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: “bluebird bio Inc (BLUE) Insider David Davidson Sells 4,000 Shares” was published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.com-unik.info/2018/02/08/bluebird-bio-inc-blue-insider-david-davidson-sells-4000-shares.html.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit